BMC Microbiology

RESEARCH

Open Access

Host cell interactions of novel antigenic membrane proteins of *Mycoplasma agalactiae*

Maysa Santos Barbosa[1,2], Lucas Miranda Marques[2,3*], Jorge Timenetsky[2], Renate Rosengarten[1], Joachim Spergser[1] and Rohini Chopra-Dewasthaly[1*]

Abstract

Background: *Mycoplasma agalactiae* is the main etiological agent of Contagious Agalactia syndrome of small ruminants notifiable to the World Organization for Animal Health. Despite serious economic losses, successful vaccines are unavailable, largely because its colonization and invasion factors are not well understood. This study evaluates the role of two recently identified antigenic proteins (MAG_1560, MAG_6130) and the cytadhesin P40 in pathogenicity related phenotypes.

Results: Adhesion to HeLa and sheep primary mammary stromal cells (MSC) was evaluated using ELISA, as well as in vitro adhesion assays on monolayer cell cultures. The results demonstrated MAG_6130 as a novel adhesin of *M. agalactiae* whose capacity to adhere to eukaryotic cells was significantly reduced by specific antiserum. Additionally, these proteins exhibited significant binding to plasminogen and extracellular matrix (ECM) proteins like lactoferrin, fibrinogen and fibronectin, a feature that could potentially support the pathogen in host colonization, tissue migration and immune evasion. Furthermore, these proteins played a detrimental role on the host cell proliferation and viability and were observed to activate pro-apoptotic genes indicating their involvement in cell death when eukaryotic cells were infected with *M. agalactiae*.

Conclusions: To summarize, the hypothetical protein corresponding to MAG_6130 has not only been assigned novel adhesion functions but together with P40 it is demonstrated for the first time to bind to lactoferrin and ECM proteins thereby playing important roles in host colonization and pathogenicity.

Keywords: Contagious agalactia, Cell adhesion, Cytopathic effects, ECM interaction, Plasminogen binding proteins, Immunomodulation, Mycoplasma pathogenicity

Introduction

Although mycoplasmas have a reduced genome they can behave as complex microorganisms [1, 2]. In the absence of a cell wall, important interactions with the host cells are carried out by their cytoplasmic membranes [3–5]. In mycoplasmas, the integral and membrane-associated proteins are exposed to the environment and play an important role in the survival and pathogenesis of the agent [1, 5].

Mycoplasmas have several lipid-associated membrane proteins (LPPs) which are able to modulate immune responses [5, 6]. Some important LPPs in *Mycoplasma* spp. have been described, such as LppQ in *M. mycoides* subsp. *mycoides* [7]; P60 in *M. capricolum* subsp. *capricolum* [8] and P30 in *M. pneumoniae* [9]. Mycoplasma LPPs are important virulence factors and targets of growth inhibitory antibodies, and may influence several functions such as apoptosis [10], antigenic variation [11],

*Correspondence: lmirandamarques@gmail.com; Rohini.Chopra-Dewasthaly@vetmeduni.ac.at
[1] Institute of Microbiology, Department of Pathobiology, University of Veterinary Medicine Vienna, Veterinaerplatz 1, Vienna A-1210, Austria
[3] Multidisciplinary Institute of Health, Federal University of Bahia, Vitória da Conquista, Brazil
Full list of author information is available at the end of the article

© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

transport of molecules [12], nuclease activity [13] and adhesion [14, 15].

In case of *M. agalactiae,* the main causative agent of Contagious agalactia syndrome in sheep and goats, few membrane proteins have been identified, such as the P30 protein [16], cytadhesin P40 [17], P48 protein [18, 19], lipoprotein MAG_5040 [13], pyruvate dehydrogenase [20] and Vpmas [21, 22]. In addition, MAG_1560 and MAG_6130 were identified by our group as novel antigenic proteins using bioinformatic analyses and demonstrated reactivity in immunoassays to sera from infected goats/sheep sera [23]. Since MAG_1560 and MAG_6130 were identified as membrane immunogenic proteins together with P40, a known cytadhesin of *M. agalactiae* [23], this study aimed to elucidate their functions. Adherence being a fundamental step for microbial colonization and infection [24, 25], these two hypothetical proteins were also evaluated for their role in adhesion to host cells together with P40 cytadhesin. Protein-protein interactions involving adhesins and components of the host extracellular matrix are integral and recurring features of bacterial pathogens [25] and were also analyzed. As bacterial adhesion is known to alter cell signaling to facilitate the spread of the pathogens by host immune evasion, internalization or biofilm formation [25, 26], these membrane proteins were further evaluated for their role in host cell signaling in vitro.

Results

Serologic cross-reactivity

No cross reaction was observed between the different rabbit polyclonal antibodies and the three recombinant proteins (P40, MAG_1560, MAG_6130) when tested via immunoassays at different concentrations (Additional file 1). Each of the three polyclonal antisera showed specific binding only to its corresponding recombinant protein and did not react with the other two proteins as depicted in Additional file 1.

P40, MAG_1560 and MAG_6130 bind HeLa and mammary stromal cells (MSC)

Immunoassays with cellular fractions of MSC and HeLa cells

The adhesion of recombinant proteins P40, MAG_1560 and MAG_6130 to cellular fractions of HeLa and MSC was analyzed by immunoassays (Fig. 1). Total proteins, as well as the cell membrane and cytoplasmic fractions, of HeLa and MSC were incubated separately with the recombinant proteins of *M. agalactiae* to demonstrate the potential of these proteins to adhere to the different cell fractions. The inhibitory effect of anti-P40, anti-MAG_1560 and anti-MAG_6130 sera was also evaluated in these adherence assays. In case of HeLa cells, anti-P40 and anti- MAG_6130 sera (pre-incubated with the respective proteins) had a significant inhibitory effect on the adhesion of corresponding recombinant proteins and cell fractions at all tested dilutions, while the adhesion of the MAG_1560 protein was weakly inhibited only at lower dilutions of the antiserum (Fig. 1). Significant inhibitory effects were observed on adhesion of MSC total proteins and cell fractions by pre-incubating all recombinant proteins with their respective antisera, even at low concentrations (dilution 1: 1280) (Fig. 1).

Adhesion assays in monolayer cell culture

Additional file 2 demonstrates the adhesion of *M. agalactiae* strains PG2 and GM139 to HeLa and sheep primary MSC cells after 4 h of infection (MOI 100). As both strains showed a similar rate of adherence for the two different eukaryotic cell cultures, adherence inhibition assays were performed with the *M. agalactiae* type strain PG2 using the standard HeLa cell line. As shown in Fig. 2, adhesion was efficiently inhibited by pre-incubating the PG2 strain with anti-P40 and anti-MAG_6130 antibodies, whereas no inhibition of adherence was observed when mycoplasma cells were pre-incubated with anti-MAG_1560 antibodies. No inhibition was observed when *M. agalactiae* was pre-incubated with pre-immune serum before adhesion assays in monolayer cell assays.

Cell viability assay

At first the optimal incubation time and plating density were determined as recommended for the AlamarBlue™ cell viability assay described under Methodology. After standardizations, a plating density of 1×10^4 cells/well for MSC and 2×10^3 cells/well for HeLa was observed to produce the required reaction with the AlamarBlue™ reagent within the linear range after 48 h of incubation at 37 °C and 5% CO_2 (Additional files 3 and 4).

When treated with 4 μg.mL^{-1} of P40, MAG_1560 or MAG_6130 proteins for 48 h, the MSC and HeLa (Fig. 3) cells showed a significant reduction in cell proliferation / viability (as measured by the reduction of the alamarBlue™ reagent) compared to the negative control (untreated cells). No significant reduction in cell viability was observed when incubating MSC or HeLa with the recombinant proteins at concentrations of 1 or 2 μg.mL^{-1} (Fig. 3).

Gene expression profile

The expression of genes involved in DNA damage signaling pathways was evaluated in cells after 48 h incubation with proteins P40, MAG_1560 and MAG_6130 (4 μg.mL^{-1}) (Fig. 4). Among the genes analyzed, 13 genes were significantly up-regulated (ATRX, BAX, CDC25A, CHEK1, CRY1, DDB2, NBN, PCNA, RAD51B, UNG, XPA, XRCC2 and XRCC3; $p < 0.05$) in cells inoculated



Fig. 1 Adhesion and adhesion inhibition immunoassays of recombinant proteins P40, MAG_1560 and MAG_6130 to HeLa (left panels) and MSC (right panels) proteins. The panels show the corresponding adhesion inhibition using antisera dilutions ranging from 1:20 to 1: 1280 for each recombinant protein. BSA was used as a negative control. (*) $p < 0.05$, (**) $p < 0.01$, (***) $p < 0.001$ represent statistically significant differences



Fig. 2 Inhibition of *M. agalactiae* adhesion to HeLa cells in monolayer cell culture. Adhesion of *M. agalactiae* strain PG2 to HeLa cells and inhibition of adhesion by pre-incubating the mycoplasma cells with the respective mono-specific antisera. Data represented as mean (± SD) of three independent experiments carried out in duplicate. Statistical analysis was performed using Student's t test. (**) $p < 0.01$, (***) $p < 0.001$ represent statistically significant differences

with P40 compared with the control unstimulated cells. In contrast, only one gene was significantly up-regulated (CDC25A; $p < 0.05$) in cells incubated with MAG_1560 and two genes (XPA and XPC; $p < 0.05$) in cells stimulated with MAG_6130 compared to the control group. As regards down-regulation, only one gene was significantly down-regulated (CDKN1A; $p < 0.05$) after stimulation with MAG 6130.

Binding assays to host proteins

The graph in Fig. 5 demonstrates the binding of the P40 protein to plasminogen even at low concentration (<2 μg. mL^{-1} of plasminogen). On the other hand, MAG_1560 and MAG_6130 proteins do not demonstrate sufficient binding to plasminogen even at high concentrations (100 μg.mL^{-1}). However, as illustrated in Fig. 5, P40 and MAG_6130 exhibit significant binding to fibrinogen, fibronectin and lactoferrin. In contrast, MAG_1560 binds only fibrinogen. No interaction was observed between proteins and BSA controls under these conditions.

Discussion

Mycoplasmas have several membrane proteins associated with lipids (LPPs). Unlike bacteria with cell walls, which have a lower number of these molecules, two thirds of the mycoplasma membrane mass corresponds to LPPs [4, 6, 27]. These molecules exposed to the bacterial surface may have the same functions as periplasmic proteins in Gram-negative bacteria [1] and are known to mediate adhesion [24], invasion [22], immunomodulation [5] and/or immune evasion [28], playing important roles in mycoplasma pathogenicity [21].

Cytadherence in mycoplasmas is essential for colonization and infection and considered a major pathogenicity factor. These bacteria have incomplete metabolic pathways and adhere to host cells to obtain nutrients [29]. The best characterized adhesins in mycoplasmas are those of the human mycoplasmas, *M. pneumoniae* and *M. genitalium*, and the bird pathogen *M. gallisepticum*. These microorganisms have an "adhesion organelle" which consists of a terminal structure with a central filament, formed by several adhesins [30]. Other mycoplasmas do not have a specific structure for adhesion but exhibit cytadherence capabilities mediated by other proteins, including "moonlighting" proteins, such as pyruvate dehydrogenase of *M. gallisepticum* [31], fructose-1,6-bisphosphate aldolase of *M. bovis* [32], elongation factor Tu of *M. pneumoniae* and *M. hyopneumoniae* [33], GroEL and DnaK of *M. pneumoniae* [34], P146 [35], Mhp107 [36] and P116 [37] of *M. hyopneumoniae.* For *M. agalactiae*, P40 [17], pyruvate dehydrogenase [20] and Vpma lipoproteins [22] have been described as adhesins and / or invasins. In



Fig. 3 Effect of recombinant proteins of *M. agalactiae* on the viability of eukaryotic cells. The sheep MSC and HeLa cells were seeded in 96-well plates and after overnight incubation treated with (**A** and **D**) 1, (**B** and **E**) 2 and (**C** and **F**) 4 μg.mL^{-1} of the P40, MAG_1560 or MAG_6130 proteins. After 48 h of treatment, alamarBlue™ reagent was added and its reduction was monitored spectrophotometrically at 570 nm and 600 nm. Statistical analysis was performed using Student's t test. (*) $p < 0.05$, (**) $p < 0.01$ represent statistically significant differences

addition, it has also been demonstrated in mycoplasmas that adhesins can recognize more than one target, and one target can also bind to more than one adhesin [38].

In this study, HeLa and MSC (mammary stromal cells) cells were used in the adhesion assays. In previous studies, *M. agalactiae* PG2 strain has shown similar efficient binding to both cells [22, 39]. Current adhesion assays demonstrated that *M. agalactiae* strains PG2 and GM139 adhere to eukaryotic cells in a similar way, as shown here (Additional file 2) for both HeLa and



Fig. 4 - Gene Expression profiles of cells treated with recombinant *M. agalactiae* proteins. Panels show up-regulated and down-regulated genes in cells stimulated with recombinant proteins P40, MAG_1560 and MAG_6130 for 48 h compared to the unstimulated control group. *Statistical significance ($p < 0,05$) (Student's T-test of the replicate 2^(− Delta CT) values for each gene in the control group and treatment groups)

MSC, although the adhesion rate observed in this study (between 10 and 15%) was lower than the adherence rate observed in previous studies using the same protocol and cells (approximately 33% for HeLa and 45% for MSC) [22, 39]. The difference in the adherence rate found in this study and the adherence reported in previous studies is explained solely by the experimental variation since this assay was performed in replicates and under the same conditions reported in the literature. Lower adherence rates were observed using MOI less than 100 (Additional file 5). Evaluation of the specific ability of anti-P40, anti-MAG_1560 and anti-MAG_6130 antibodies to inhibit the binding of *M. agalactiae* PG2 demonstrated that the hypothetical protein MAG_6130 has an adhesion capacity similar to P40 (Fig. 2), which is a well-known cytadhesin of *M. agalactiae* [17]. Moreover, same results were obtained using two different evaluation methods, namely inhibition of adhesion to cellular fractions in immunoassays (Fig. 1) and to monolayers of HeLa and MSC cultures (Fig. 2 and Additional file 2). On the other hand, the adhesion of MAG_1560 was inhibited only in adhesion assays using cell fractions (weakly inhibited) and not in assays employing HeLa cell monolayers (Figs. 1 and 2). Perhaps in the latter case, expression of MAG_1560 is regulated by environmental factors or there is interference between individual adhesins. Bacteria expressing multiple adhesins are known to vary their adhesion profile by controlled expression of individual adhesins at different stages of infection [40]. A possible hypothesis could be that the Hela cells do not have receptors that allow adhesion of MAG_1560, and the binding demonstrated in Fig. 1 is rather nonspecific. Though unexpected, the recombinant proteins bind to all eukaryotic cell fractions (Fig. 1) and, as already mentioned, this binding is significantly inhibited by specific hyperimmune serum (except MAG_1560 in HeLa) and not by pre-immune serum. Moreover, some other mycoplasma proteins have also been shown to bind to both cellular and cytosolic protein fractions. For instance, the recombinant NOX protein of *Mycoplasma bovis*, a close phylogenetic relative of *M. agalactiae,* was shown to bind to both the membrane proteins and cytosolic proteins of eukaryotic host cells [41].

Despite several studies of mycoplasma adhesion to host cells, little is known about the involved cell receptors and their interactions. It has been shown that extracellular β-actin [42], cyclophilin A [43], sialic acid [44, 45] and sialylated glycoconjugates [46] act as mycoplasma receptors on different cells. Future in-depth studies should be carried out to identify the receptors involved in *M. agalactiae* adhesion to eukaryotic cells, as well as receptor domains and adhesion at different stages of cell maturation.

Interactions between host proteins and mycoplasma proteins have been described in few cases [32, 34, 41, 47–50]. In this study, binding assays to host proteins



Fig. 5 *M. agalactiae* binding to plasminogen and extracellular matrix proteins. Recombinant proteins P40, MAG_1560, MAG_6130 were applied to quantify their binding to plasminogen, fibrinogen, lactoferrin and fibronectin by indirect ELISA. Data represented with the mean (± SD). Statistical analysis was performed using Two way anova with Bonferroni post test. (***) $p < 0.001$, (**) $p < 0.01$, (*) $p < 0.05$

demonstrated that, mainly, P40 and MAG_6130 play a role in *M. agalactiae*'s binding to these molecules (Fig. 5). P40 binds to plasminogen, but it has not been evaluated whether P40 is also able to activate plasminogen to plasmin and whether ionic interactions and the amino acid lysine interfere in this interaction. Binding and/or activation of plasminogen by mycoplasmas/recombinant proteins has been demonstrated by rMsEno (*M. synoviae)* [48], Pdh (*M. pneumoniae)* [51], PdhA and PdhB (*M. gallisepticum)* [31], Enolase (*M. hyopneumoniae*) [38], *M. fermentans* [52].

Plasminogen is immobilized on the surface of some bacteria by the presence of receptors, which allow its conversion to plasmin and assist bacterial migration through the tissue barrier [34, 49]. Additionally, plasminogen bound to the pathogen's surface can also contribute to degradation of C3b and C5, thereby inhibiting the activation of the three pathways of the complement system [53, 54]. Thus, in addition to P40 being a cytadhesin it might as well be involved in evading the host immune response via plasminogen binding and act as a moonlighting protein. Although MAG_6130 protein does not bind to plasminogen, it can interact with molecules of the host, namely fibronectin, lactoferrin and fibrinogen, and contribute to the adhesion of *M. agalactiae* to host cells (Fig. 5). Interactions between bacterial proteins and fibronectin and fibrinogen facilitate the attachment of the microorganisms to the surface of the host cell via integrin, contributing to adhesion, invasion and formation of bacterial biofilm [26, 55]. Furthermore, binding of P40 and MAG 6130 to lactoferrin could also assist *M. agalactiae* in the acquisition of iron for growth and protection against cationic antimicrobial peptides as described for other bacterial pathogens [56]. Overall, the hypothetical protein MAG_6130 is not only involved in *M. agalactiae's* adhesion to host cells like the cytadhesin P40, it might as well play other important roles in the pathogen's survival and immune evasion capabilities inside the host, and act as a "moonlighting" protein.

Adhesion of mycoplasmas to host cells can lead to cell damage (Rotten, 2003). *M. agalactiae* has been earlier demonstrated to induce cytopathic effects in infected host cells [57]. This study shows that P40, MAG_1560 and MAG_6130 are capable of altering the cell viability / proliferation of eukaryotic host cells (Fig. 3), thereby contributing to the process of cell destruction in host cells infected with *M. agalactiae*. A similar effect of membrane proteins on cell destruction has been reported in other mycoplasmas [58]. In *M. pneumoniae* the absence of phosphorylation in HMW1, HMW3, the major

adhesin P1, and the surface protein MPN474 alters the function of the terminal organelle resulting in decreased adherence and loss of cytotoxicity [59]. Further studies are needed to assess whether these membrane proteins are involved in cell destruction by inducing pro-inflammatory cytokines (IL-1 and IL-6), NO and ROS.

Apoptotic events have been demonstrated to occur in several pathogenic animal mycoplasma species [57, 60–65] and human mycoplasmas [66] by the activation of caspases, MAPK, ROS, and the ERK signaling pathway [10, 67]. More specifically, it has been shown that certain proteins, such as MbovNase nuclease [68], P48 [69] and MbovP280 [70] of *M. bovis;* Mhp597 and P68 of *M. hyopneumoniae* [71, 72] and GroEL, of *M. gallisepticum* [73] trigger pro-apoptotic genes by the activation of MAPK, BAK, and caspases or by unknown pathways. In this study, we demonstrate a similar up-regulation profile of genes in cells stimulated by membrane proteins of *M. agalactiae*, mainly by P40. For instance, an increased expression of *ATRX*, which acts on the remodeling of chromatin and is related to the MAPK cascade [74] was observed. Also, the expression of *Bax*, a known activator of caspase 9 and caspase 3 that allows release of cytochrome c and other molecules through channels in the mitochondrial membrane was enhanced [75]. Altogether, these data point towards the occurrence of pro-apoptotic events. Additionally, an increase in the expression of molecules that act in response to DNA damage was observed. Initially RAD51 is recruited in a manner dependent on ATM and NBN, the latter guides MRE11A and RAD50 to the DNA damage site, where it interacts with the ATM protein [76, 77]. RAD51 in complex with XRCC3, promotes the activation of Chek2. ATR is also activated and phosphorylates Chek1 resulting in the interruption of the cell cycle. DDB2 also downregulates p21 by proteolysis, allowing cell death [78]. Overall, due to the severity of the damage, the cell undergoes premature apoptosis [79, 80]. Moreover, plasminogen binding has also been reported to be associated with an increased rate of apoptosis [81].

Conclusion

Only a few *M. agalactiae* proteins have been functionally characterized to play important roles in its pathogenicity, including P40 [17], P30 [16], PdhB [20], Vpmas [22] and MAG_5040 [13]. In this study, hypothetical protein corresponding to MAG_6130 has not only been assigned novel adhesion functions but together with P40 it is demonstrated for the first time to bind lactoferrin and ECM proteins. All these characteristics could have far-reaching effects on the pathogenicity as also seen for PavB of *Streptococcus pneumoniae*, which is also an adhesin, similarly interacts with plasminogen and fibronectin, and its mutants were demonstrated to be attenuated and out-competed by wild type strain in a mice co-infection study [82]. Furthermore, P40 binds plasminogen and was shown to induce DNA damage. Overall, these multifunctional proteins may contribute to colonization, immune evasion, and establishment of the *M. agalactiae* infection, and are anticipated to serve as important serodiagnostic and vaccine candidates.

Methodology

Bacterial strains, cell lines and culture conditions

Mycoplasma agalactiae strain GM139 [83] and type strain PG2 were grown at 37 °C in SP4 medium supplemented with penicillin and phenol red as described earlier [84]. For cell infections, HeLa-229 cells (CCL-2.1, ATCC, USA) and sheep primary mammary stromal cells (MSCs) (MSC cells were obtained from an adult lactating sheep and characterized via immunohistochemistry in a previous study [39] and were stored in liquid nitrogen until the moment of use) were cultured as reported previously [39]. Briefly, HeLa cells were cultured in MEM medium containing 10% heat-inactivated fetal bovine serum and MSC cells were cultured in DMEM high glucose (89%) medium containing 1% L-glutamine and 10% heat-inactivated fetal bovine serum. For adhesion assays, 5×10^4 cells/well were plated on 24-well plates (CELLSTAR®, Greiner Bio-One GmbH, Germany) 48 h before infection. For cell viability tests, 1×10^4 cells/well for MSC and 2×10^3 cells/well for HeLa were plated in 96-well plates 24 h before inoculation. HeLa and MSC cells were used at passage 25 and passage 6, respectively. The cell cultures were periodically tested for mycoplasma contamination by culture and/ or PCR [85].

Expression and purification of recombinant proteins

Recombinant proteins [P40, MAG_1560 (MAG_RS00795), MAG_6130 (MAG_RS03125)] were expressed in *Escherichia coli* and purified on affinity columns as described by Barbosa et al. (2020) [23]. Briefly, *E. coli* BL21 Star™ (DE3) One Shot containing the expression vector (pET28a) was cultured in medium containing kanamycin and IPTG, and the proteins were purified using nickel chelating resin (HisTrap™ HP, GE Healthcare Bio-Sciences Corp., USA). Proteins were assessed by 12% SDS-PAGE stained with Coomassie Blue and Western blots using the primary antibody against the 6x-His Epitope Tag (Invitrogen™) (Additional file 6) and subjected to membrane dialysis.

Mono-specific polyclonal antibodies

Polyclonal antibodies were produced in New Zealand rabbits as ethically approved (FMUSP – 944/2017; ICB – 123/2016 /CEUA) and described earlier [23]. All methods

were performed in accordance with the relevant guidelines and regulations. Briefly, rabbits were first immunized with 500 µg of recombinant protein emulsified in complete Freund's adjuvant (Sigma-Aldrich®) (v/v). Subsequently, two additional immunizations were performed at two-week intervals. On the 42nd day of immunization, the animals were submitted to cardiac puncture exsanguination. The purification of antisera using G protein columns and the titer were realized previously by ELISA [23].

Cross-reactivity between polyclonal antibodies and the P40, MAG_1560, MAG_6130 proteins was assessed by immunoassays. The latter were performed on polystyrene plates (Nunc™, Thermo Scientific™) coated with 500, 1000 and 2000 ng.mL^{-1} of each recombinant protein separately after dilution in carbonate-bicarbonate buffer pH 9.6 (100 µL/well) for 16 h at 4 °C in humid chamber. The plates were washed with TBS - Tween 20 (TBST) (0.05%) and non-specific binding sites were blocked for one hour at 37 °C with 5% skimmed milk in TBST (200 µL/well). The plates were rewashed and the monospecific polyclonal antibodies were added (100 µL/well) at different dilutions (0.5 µg.mL^{-1}, 0.25 µg.mL^{-1},0.125 µg.mL^{-1}). Then the microplates were incubated at room temperature for 1.5 h. Subsequently, the microplates were washed again and the secondary antibody conjugated with peroxidase (Goat anti-Rabbit IgG, HRP conjugate - Invitrogen™) was added at a dilution of 1:5000 in TBST containing 5% skimmed milk (100 µL/well). After incubation at room temperature for 1.5 h, the plates were washed again. The reactions were developed using the chromogenic substrate OPD (o-Phenylenediamine Dihydrochloride, Thermo Scientific™) with the addition of hydrogen peroxide for 10 min. The reaction was stopped with 50 µL of 1 N sulphuric acid before optical density (O.D.) measurements were recorded on a microplate reader at 492 nm.

In vitro adhesion assays

Immunoassays

To test the quantitative binding of recombinant proteins to HeLa and MSC an immunoassay was used. HeLa and MSC were used since the ability of *M. agalactiae* to adhere to both these host cells is previously known [22, 39]. Initially, 96-well plates were coated at 4 °C overnight with proteins (10 µg/well): total cell proteins, cell membrane or the cytosolic fractions of HeLa or MSC in bicarbonate-carbonate sodium buffer (pH 9.6). The protein fractions of eukaryotic cells i.e. HeLa and MSC, were obtained after extraction with 1% Triton TX-114 as previously described [86, 87]. For the adhesion test, the wells were blocked with 5% milk before adding 1000 or 2000 ng.mL^{-1} of recombinant proteins diluted in TBST (100 µL/well). The reaction was incubated at 37 °C for 1.5 h and the wells washed thrice with TBST followed by incubation with the respective anti-recombinant protein antibody at room temperature for 1.5 h, anti-P40 (5 µg.mL^{-1}), anti-MAG_1560 (0.1 µg.mL^{-1}), and anti-MAG_6130 (1 µg.mL^{-1}) (100 µL/well). After washing, anti-rabbit IgG-HRP antibody (1: 5000; 100 µL/well) was added and the plate again incubated at room temperature for 1.5 h before recording the reaction as described above. BSA was used as a negative control.

For the adhesion inhibition assays, each antiserum against the specific recombinant protein (1 mg.mL^{-1}) was serially diluted from 1/20 to 1/1280. Each of these dilutions (100 µL) were pre-incubated with 1000-2000 ng.mL^{-1} of recombinant protein in 100 µl TBST at 37 °C for 1 h. Subsequently, each mixture was added to the wells previously coated with the eukaryotic cells' protein fractions. The reaction and detection proceeded as described above [34, 41].

Monolayer cell cultures

M. agalactiae strains PG2 and GM139 were incubated with HeLa and MSC (at a MOI of 100, as previously described by Hegde et al., 2015a, 2018 [22, 39]) for 4 h at 37 °C and 5% CO_2 to assess their cell adhesion capacity. Non-adhered mycoplasmas were removed by three washes with PBS and serial dilutions of the cell suspension plated on SP4 agar after trypsinization. As controls, mycoplasma suspensions were incubated in the absence of eukaryotic cells in parallel wells to quantify the CFU after 4 h of incubation. Adherence was calculated using the ratio of the CFU.mL^{-1} of the adhered mycoplasmas to the CFU.mL^{-1} of total mycoplasmas in the given time [22, 39].

For the adhesion inhibition assays, *M. agalactiae* was separately pre-incubated at 37 °C for 1 h with each of the three antisera (10:1, v/v) against the specific recombinant proteins. The mycoplasma-antibody suspension was then added to the eukaryotic cells and further incubated at 37 °C, 5% CO_2 for 4 h. The percentage adherence was calculated as described above [22].

Cell viability assays

Initially the optimal incubation time and plating density was determined. For that, $2.5 \times 10,^3$ $5 \times 10,^3$ 1×10^4 and 2×10^4 cells/ well (MSC) or $5 \times 10,^2$ $1 \times 10,^3$ $2 \times 10,^3$ 2.5×10^3 and 5×10^3 HeLa cells/ well were incubated overnight. After washing the cells with PBS, 90 µL of media followed by 10 µL of alamarBlue™ HS Cell Viability Reagent Invitrogen™ was added to each well. The plates were incubated at 37 °C, 5% CO_2 for 24 h, 48 h and 72 h. The absorbance of the reaction was measured at a wavelength of 570 nm and 600 nm at each hour for 8 h,

10 h and 24 h after incubation with the reagent. The percentage reduction of alamarBlue™ reagent using absorbance readings was calculated following manufacturer's instructions.

For the cell viability assay, 1×10^4 MSC cells/ well or 2×10^3 HeLa cells/ well were plated in 96 well plates. After overnight incubation at 37 °C and 5% CO_2, the cells were washed with PBS and incubated with recombinant proteins P40, MAG_1560 or MAG_6130 (1, 2 and 4 μg.mL^{-1}; 100 μL/well) for 48 h under the same conditions. Prior to use in cell stimulation, the recombinant proteins were filtered through 0.22 μm filters and preincubated for 2 h with polymyxin B (lipopolysaccharide-neutralizing agent) at 1000 U.mL^{-1} [10]. Subsequently, the alarmarBlue™ reagent was added to each well and readings recorded after every hour, for 4-6 h using a microplate reader to calculate the percentage of reduction of the alarmarBlue™ reagent as described above.

Gene expression analysis

Gene expression of the DNA damage-signaling pathway was evaluated by qPCR array methodology. The mRNA was extracted using RNAeasy mini Kit (Qiagen-SABioscience) following the protocol provided by the manufacturer. The cDNA was obtained by means of a retro-transcription (RT) from the mRNA, using the SuperScript™ IV Reverse Transcriptase kit with addition of oligonucleotides complementary to the poly-A tail of the mRNA, (Oligo dT) and inhibitor of RNAse. The obtained cDNA was subjected to analysis with the use of RT^2 Profiler™ qPCR Array Human DNA Damage Signaling Pathway kit (Qiagen-SABioscience) for the expression of 84 genes involved in the host response to DNA damage. All procedures, data analysis and statistical analysis were performed according to the manufacturer's instructions and software Qiagen-SABioscience (https://dataanalysis.qiagen.com/pcr/arrayanalysis.php). The data are presented in fold change values for each gene relative to expression in the control group (basal expression) and the stimulated group.

Binding assays to host proteins

The plasminogen binding assay was performed in 96-well plates covered with recombinant proteins P40, MAG_1560 or MAG_6130 (500 ng/100 μL/ well) diluted in bicarbonate carbonate buffer pH 9.6 for 16 h at 4 °C, in a humid chamber, followed by blocking with 5% milk in TBST (200 μL/well) for 2 h at 37 °C. After five washes with TBST, the wells were incubated with different concentrations of bovine plasminogen (1.562 and 100.0 μg.mL^{-1}; 100 μL/well) (Sigma-Aldrich®) in PBS pH 7.4 at 37 °C for 1.5 h. Binding to plasminogen was detected by the addition of 100 μL/well of 1: 2000 diluted rabbit anti-plasminogen IgG (Abcam). Wells incubated with BSA served as negative control for plasminogen binding. The reactions were quantified as described earlier [34, 41]. Bovine plasminogen is similar to plasminogen from goats and sheep (coverage $> 92\%$ and identity $> 88\%$).

For the protein binding assays, extracellular matrix (ECM) proteins (fibronectin and fibrinogen) and lactoferrin (Sigma-Aldrich®) (5 and 50.0 μg.mL^{-1}) were individually diluted in bicarbonate carbonate buffer pH 9.6 and added 100 μL/ well in 96-well plates for 16 h at 4 °C, in a humid chamber, followed by blocking with 5% milk in TBST (200 μL/ well) for 2 h at 37 °C. After five washes with TBST, the wells were incubated with recombinant proteins P40, MAG_1560 and MAG_6130 (500 ng/100 μL/ well) in PBS pH 7.4 at 37 °C for 1.5 h. The plates were re-washed and the mono-specific polyclonal antibodies were added at 1:1600 dilution in TBST and incubated for 1 h at 37 °C. Subsequently, the microplates were washed again and the binding was detected by the addition of diluted anti-Rabbit IgG HRP conjugate 1: 10000 (100 μL/ well) (Sigma-Aldrich®). Wells incubated with BSA were used as negative controls for binding [88]. The reactions were quantified as described above.

Statistical analysis

Statistical analysis was performed using the GraphPad-Prism 6.0 program (GraphPad Software, USA). To evaluate the antigen-antibody cross-reaction and adhesion to plasminogen, lactoferrin and ECM proteins, the non-parametric Two way ANOVA test with Bonferroni post test was performed. To evaluate the adhesion between recombinant proteins and fractions of eukaryotic cells, One way ANOVA non-parametric test with Dunnett post test was used, whereas to analyze the inhibition of *M. agalactiae* adhesion in monolayer cell cultures and cell viability, Student's t test was performed. The statistical analyses were assessed from at least two independent experiments carried out in duplicates or triplicates. Data is expressed as mean ± standard deviation. Statistical differences were considered significant when $p < 0.05$ using a 95% confidence interval.

Abbreviations

ECM: Extracellular matrix; IPTG: Isopropyl-β-d-thiogalactopyranoside; LPP: Lipid-associated membrane proteins; MOI: Multiplicity of infection; MSC: Sheep primary mammary stromal cells; O.D.: Optical density; OPD: o-Phenylenediamine Dihydrochloride; SD: Standard deviation; SDS: Sodium dodecyl sulfate; SDS-PAGE: (SDS)-polyacrylamide gel; Vpma: Variable proteins of *Mycoplasma agalactiae*.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12866-022-02512-2 .

Additional file 1. Analysis of cross reactivity of the three rabbit antisera. Cross reactivity between recombinant proteins (P40, MAG_1560 and MAG_6130) at concentrations of 500, 1000 and 2000 µg.mL^{-1} and the corresponding rabbit polyclonal antibodies evaluated via immunoassays at concentrations of 0.5, 0.25 and 0.125 mg.mL^{-1}. Two way ANOVA test with Bonferroni post test was performed. Data expressed as mean ± standard deviation. (***) $p < 0.001$.

Additional file 2. Adhesion of *M. agalactiae* strains PG2 and GM139 to HeLa and sheep primary mammary stromal cells - MSCs. Adhesion rate of *M. agalactiae* after 4 h of infection to HeLa and MSC cells (MOI 100). Data represent the mean (± SD) of three independent experiments carried out in duplicate. Statistical analysis was performed using One way Anova with Dunnett post test.

Additional file 3. Percentage reduction of alamarBlue™ reagent in MSC at different cell numbers and incubation times. Four different amounts of cells per well were plated and incubated at (A) 24 h, (B) 48 h and (C) 72 h at 37 °C, 5% CO_2. The alamarBlue™ reagent (10 µL/well) was added and the readings taken at 570 nm and 600 nm to determine the optimal incubation time and plating density.

Additional file 4. Percentage reduction of alamarBlue™ reagent in HeLa at different cell numbers and incubation times. Five different amounts of cells per well were plated and incubated at (A) 24 h and (B) 48 h at 37 °C, 5% CO_2. The alamarBlue™ reagent (10 µL/well) was added and readings taken at 570 nm and 600 nm to determine the optimal incubation time and plating density.

Additional file 5. Adhesion of *M. agalactiae* type strain PG2 to HeLa. Adhesion rate of *M. agalactiae* after 4 h of incubation with HeLa cells using different MOI. Data represent the mean (± SD) of three independent experiments carried out in duplicate.

Additional file 6. Purity profile of the three recombinant proteins of *Mycoplasma agalactiae.* A) 12%-polyacrylamide gel electrophoresis stained with Coomassie Blue, MW: Molecular weight Novex® Sharp Unstained Protein Standard (Invitrogen™, USA). B) Western blot performed with anti-histidine antibody (6x-His Epitope Tag, Invitrogen™, USA), MW: Molecular weight Novex® Sharp Pre-stained Protein Standard (Invitrogen™, USA). Lane 1: P40 (42 KDa); Lane 2: MAG_1560 (32 KDa); Lane 3: MAG_6130 (24 KDa).

Acknowledgements
We also thank Aricelma P. França for invaluable technical assistance.

Authors' contributions
MSB, LMM, JT and RCD conceptualized and planned the research; MSB performed the experiments, prepared figures; MSB, LMM and RCD analyzed the data; MSB and RCD wrote the manuscript; JT, JS and RR gave strategical inputs for the project LMM, RR, JS, RCD reviewed the manuscript for critical and important content. All authors contributed to the article and approved the submitted version.

Funding
This work was supported by the São Paulo Research Foundation (FAPESP) grant numbers 2016/23306-6, 2017/25686-3 and 2019/ 03425-9, the latter covered the research and stay of MSB at the University of Veterinary Medicine Vienna, Austria and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) (Finance Code 001) and CAPES-PRINT/UFBA (Tema: Inovações em saúde e ambiente como estratégias para a redução das desigualdades sociais e melhoria da qualidade de vida).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
The experiments were approved by the Animal Use Ethics Committees (CEUA) of the Faculty of Medicine of the University of São Paulo (FMUSP - 944/2017), the Biomedical Sciences Institute, University of São Paulo (ICB - 123/2016 / CEUA), and University of Veterinary Medicine Vienna (BMWFW-68.205/0106-WF/II/3b/2014). The study is reported in accordance with ARRIVE guidelines.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
[1]Institute of Microbiology, Department of Pathobiology, University of Veterinary Medicine Vienna, Veterinaerplatz 1, Vienna A-1210, Austria. [2]Present Address: Department of Microbiology, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil. [3]Multidisciplinary Institute of Health, Federal University of Bahia, Vitória da Conquista, Brazil.

Received: 24 November 2021 Accepted: 30 March 2022
Published online: 08 April 2022

References
1. Browning GF, Marenda MS, Noormohammadi a H, Markham PF. The central role of lipoproteins in the pathogenesis of mycoplasmoses. Vet Microbiol. 2011;153:44–50. https://doi.org/10.1016/j.vetmic.2011.05.031.
2. Rosengarten R, Citti C, Glew M, Lischewski A, Droesse M, Much P, et al. Host-pathogen interactions in mycoplasma pathogenesis: virulence and survival strategies of minimalist prokaryotes. Int J Med Microbiol. 2000;290:15–25. https://doi.org/10.1016/S1438-4221(00)80099-5.
3. Santos-Junior MN, Rezende IS, Souza CLS, Barbosa MS, Campos GB, Brito LF, et al. *Ureaplasma diversum* and its membrane-associated lipoproteins activate inflammatory genes through the NF-κB pathway via toll-like receptor 4. Front Microbiol. 2018;9. https://doi.org/10.3389/fmicb.2018.01538.
4. Chambaud I, Wróblewski H, Blanchard A. Interactions between Mycoplasma lipoproteins and the host immune system. Trends Microbiol. 1999;7:493–9. https://doi.org/10.1016/S0966-842X(99)01641-8.
5. Christodoulides A, Gupta N, Yacoubian V, Maithel N, Parker J, Kelesidis T. The role of lipoproteins in Mycoplasma-mediated immunomodulation. Front Microbiol. 2018;9. https://doi.org/10.3389/fmicb.2018.01682.
6. Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiolmolbiolrev. 1998;62:1094–156.
7. Abdo EM, Nicolet J, Frey J. Antigenic and genetic characterization of lipoprotein LppQ from *Mycoplasma mycoides* subsp. *mycoides* SC. Clin Diagn Lab Immunol. 2000;7:588–95 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=95919&tool=pmcentrez&rendertype=abstract.
8. Alberti A, Robino P, Chessa B, Rosati S, Addis MF, Mercier P, et al. Characterisation of *Mycoplasma capricolum* P60 surface lipoprotein and its evaluation in a recombinant ELISA. Vet Microbiol. 2008;128:81–9. https://doi.org/10.1016/j.vetmic.2007.09.020.
9. Varshney AK, Chaudhry R, Kabra SK, Malhotra P. Cloning, expression, and immunological characterization of the P30 protein of *Mycoplasma pneumoniae*. Clin Vaccine Immunol. 2008;15:215–20. https://doi.org/10.1128/CVI.00283-07.
10. Ni B, Bai F, Wei Y, Liu M, Feng Z, Xiong Q, et al. Apoptosis induced by lipid-associated membrane proteins from *Mycoplasma hyopneumoniae* in a porcine lung epithelial cell line with the involvement of caspase 3 and the MAPK pathway. Genet Mol Res. 2015;14:11429–43. https://doi.org/10.4238/2015.September.25.10.
11. Citti C, Nouvel L-X, Baranowski E. Phase and antigenic variation in mycoplasmas. Future Microbiol. 2010;5:1073–85.
12. Schmidt JA, Browning GF, Markham PF. *Mycoplasma hyopneumoniae* mhp379 is a Ca2+−dependent, sugar-nonspecific exonuclease exposed on the cell surface. J Bacteriol. 2007;189:3414–24.

13. Cacciotto C, Addis MF, Coradduzza E, Carcangiu L, Nuvoli AM, Tore G, et al. *Mycoplasma agalactiae* MAG_5040 is a Mg2+−dependent, sugar-non-specific SNase recognised by the host humoral response during natural infection. PLoS One. 2013;8:e57775. https://doi.org/10.1371/journal.pone.0057775.
14. Belloy L, Vilei EM, Giacometti M, Frey J. Characterization of LppS, an adhesin of *Mycoplasma conjunctivae*. Microbiology. 2003;149:185–93.
15. Iverson-Cabral SL, Wood GE, Totten PA. Analysis of the *Mycoplasma genitalium* MgpB adhesin to predict membrane topology, investigate antibody accessibility, characterize amino acid diversity, and identify functional and immunogenic epitopes. PLoS One. 2015;10:1–26. https://doi.org/10.1371/journal.pone.0138244.
16. Fleury B, Bergonier D, Berthelot X, Schlatter Y, Frey J, Vilei EM. Characterization and analysis of a stable serotype-associated membrane protein (P30) of *Mycoplasma agalactiae*. J Clin Microbiol. 2001;39:2814–22. https://doi.org/10.1128/JCM.39.8.2814-2822.2001.
17. Fleury B, Bergonier D, Berthelot X, Peterhans E, Frey J, Vilei EM. Characterization of P40, a cytadhesin of *Mycoplasma agalactiae*. Infect Immun. 2002;70:5612–21. https://doi.org/10.1128/IAI.70.10.5612.
18. Chessa B, Pittau M, Puricelli M, Zobba R, Coradduzza E, Dall P, et al. Genetic immunization with the immunodominant antigen P48 of *Mycoplasma agalactiae* stimulates a mixed adaptive immune response in BALBc mice. Res Vet Sci. 2009;86:414–20. https://doi.org/10.1016/j.rvsc.2008.09.010.
19. Rosati S, Pozzi S, Robino P, Montinaro B, Conti A, Fadda M, et al. P48 major surface antigen of *Mycoplasma agalactiae* is homologous to a malp product of *Mycoplasma fermentans* and belongs to a selected family of bacterial lipoproteins. Infect Immun. 1999;67:6213–6 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=97020&tool=pmcentrez&rendertype=abstract.
20. Hegde S, Rosengarten R, Chopra-Dewasthaly R. Disruption of the pdhB pyruvate dehydrogenase gene affects Colony morphology, in vitro growth and cell invasiveness of *Mycoplasma agalactiae*. PLoS One. 2015;10:e0119706. https://doi.org/10.1371/journal.pone.0119706.
21. Chopra-Dewasthaly R, Spergser J, Zimmermann M, Citti C, Jechlinger W, Rosengarten R, et al. Vpma phase variation is important for survival and persistence of *Mycoplasma agalactiae* in the immunocompetent host. PLoS Pathog. 2017;13. https://doi.org/10.1371/journal.ppat.1006656.
22. Hegde S, Zimmermann M, Rosengarten R, Chopra-Dewasthaly R. Novel role of Vpmas as major adhesins of *Mycoplasma agalactiae* mediating differential cell adhesion and invasion of Vpma expression variants. Int J Med Microbiol. 2018;308:263–70. https://doi.org/10.1016/j.ijmm.2017.11.010.
23. Barbosa MS, Alves RPDS, de Souza Rezende I, Pereira SS, Campos GB, Freitas LM, et al. Novel antigenic proteins of *Mycoplasma agalactiae* as potential vaccine and serodiagnostic candidates. Vet Microbiol. 2020;251. https://doi.org/10.1016/j.vetmic.2020.108866.
24. Vengadesan K, Narayana SVL. Structural biology of gram-positive bacterial adhesins. Protein Sci. 2011;20:759–72. https://doi.org/10.1002/pro.613.
25. Cozens D, Read RC. Anti-adhesion methods as novel therapeutics for bacterial infections. Expert Rev Anti-Infect Ther. 2012;10:1457–68. https://doi.org/10.1586/eri.12.145.
26. Stones DH, Krachler AM. Fatal attraction: how bacterial adhesins affect host signaling and what we can learn from them. Int J Mol Sci. 2015;16:2626–40. https://doi.org/10.3390/ijms16022626.
27. You X, Zeng Y, Wu Y. Interactions between mycoplasma lipid-associated membrane proteins and the host cells. J Zhejiang Univ Sci B. 2006;7:342–50. https://doi.org/10.1631/jzus.2006.B0342.
28. Czurda S, Hegde SM, Rosengarten R, Chopra-Dewasthaly R. Xer1-independent mechanisms of Vpma phase variation in *Mycoplasma agalactiae* are triggered by Vpma-specific antibodies. Int J Med Microbiol. 2017;307:443–51. https://doi.org/10.1016/j.ijmm.2017.10.005.
29. Rottem S. Interaction of mycoplasmas with host cells. Physiol Rev. 2003;83:417–32. https://doi.org/10.1152/physrev.00030.2002.
30. Waites KB, Talkington DF. *Mycoplasma pneumoniae* and its role as a human pathogen. Society. 2004;17:697–728.
31. Qi J, Zhang F, Wang Y, Liu T, Tan L, Wang S, et al. Characterization of *Mycoplasma gallisepticum* pyruvate dehydrogenase alpha and beta subunits and their roles in cytoadherence. PLoS One. 2018;13:e0208745. https://doi.org/10.1371/journal.pone.0208745.
32. Gao X, Bao S, Xing X, Fu X, Zhang Y, Xue H, et al. Fructose-1,6-bisphosphate aldolase of *Mycoplasma bovis* is a plasminogen-binding adhesin. Microb Pathog. 2018;124:230–7. https://doi.org/10.1016/j.micpath.2018.08.032.
33. Widjaja M, Harvey KL, Hagemann L, Berry IJ, Jarocki VM, Raymond BBA, et al. Elongation factor Tu is a multifunctional and processed moonlighting protein. Sci Rep. 2017;7:11227. https://doi.org/10.1038/s41598-017-10644-z.
34. Hagemann L, Gründel A, Jacobs E, Dumke R. The surface-displayed chaperones GroEL and DnaK of *Mycoplasma pneumoniae* interact with human plasminogen and components of the extracellular matrix. Pathog Dis. 2017;75:17. https://doi.org/10.1093/femspd/ftx017.
35. Bogema DR, Deutscher AT, Woolley LK, Seymour LM, Raymond BBA, Tacchi JL, et al. Characterization of cleavage events in the multifunctional cilium Adhesin Mhp684 (P146) reveals a mechanism by which *Mycoplasma hyopneumoniae* regulates surface topography. 2012.
36. Seymour LM, Falconer L, Deutscher AT, Minion FC, Padula MP, Dixon NE, et al. Mhp107 is a member of the multifunctional Adhesin family of *Mycoplasma hyopneumoniae*. J Biol Chem. 2011;286:10097–104. https://doi.org/10.1074/jbc.M110.208140.
37. Seymour LM, Deutscher AT, Jenkins C, Kuit TA, Falconer L, Minion FC, et al. A processed multidomain *Mycoplasma hyopneumoniae* Adhesin binds Fibronectin, plasminogen, and swine respiratory cilia. J Biol Chem. 2010;285:33971–8. https://doi.org/10.1074/jbc.M110.104463.
38. Chen R, Yu Y, Feng Z, Gan R, Xie X, Zhang Z, et al. Featured species-specific loops are found in the crystal structure of Mhp Eno, a cell surface Adhesin from *Mycoplasma hyopneumoniae*. Front Cell Infect Microbiol. 2019;9:209. https://doi.org/10.3389/fcimb.2019.00209.
39. Hegde S, Gabriel C, Kragl M, Chopra-Dewasthaly R. Sheep primary cells as in vitro models to investigate *Mycoplasma agalactiae* host cell interactions. Pathog Dis. 2015;73:ftv048. https://doi.org/10.1093/femspd/ftv048.
40. Klemm P, Schembri MA. Bacterial adhesins: function and structure. Int J Med Microbiol. 2000;290:27–35. https://doi.org/10.1016/S1438-4221(00)80102-2.
41. Zhao G, Zhang H, Chen X, Zhu X, Guo Y, He C, et al. *Mycoplasma bovis* NADH oxidase functions as both a NADH oxidizing and O 2 reducing enzyme and an adhesin. Sci Rep. 2017. https://doi.org/10.1038/s41598-017-00121-y.
42. Raymond BBA, Madhkoor R, Schleicher I, Uphoff CC, Turnbull L, Whitchurch CB, et al. Extracellular actin is a receptor for *Mycoplasma hyopneumoniae*. Front Cell Infect Microbiol. 2018;8:54. https://doi.org/10.3389/fcimb.2018.00054.
43. Deng X, Dai P, Yu M, Chen L, Zhu C, You X, et al. Cyclophilin A is the potential receptor of the *Mycoplasma genitalium* adhesion protein. Int J Med Microbiol. 2018;308:405–12. https://doi.org/10.1016/j.ijmm.2018.03.001.
44. Williams CR, Chen L, Driver AD, Arnold EA, Sheppard ES, Locklin J, et al. Sialylated receptor setting influences *Mycoplasma pneumoniae* attachment and gliding motility. Mol Microbiol. 2018;109:735–44. https://doi.org/10.1111/mmi.13997.
45. Aparicio D, Torres-Puig S, Ratera M, Querol E, Piñol J, Pich OQ, et al. *Mycoplasma genitalium* adhesin P110 binds sialic-acid human receptors. Nat Commun. 2018;9:4471. https://doi.org/10.1038/s41467-018-06963-y.
46. Hamaguchi T, Kawakami M, Furukawa H, Miyata M. Identification of novel protein domain for sialyloligosaccharide binding essential to *Mycoplasma mobile* gliding. FEMS Microbiol Lett. 2019;366:16. https://doi.org/10.1093/femsle/fnz016.
47. Guo Y, Zhu H, Wang J, Huang J, Khan F, Zhang J, et al. TrmFO, a Fibronectin-binding Adhesin of *Mycoplasma bovis*. Int J Mol Sci. 2017;18:1732. https://doi.org/10.3390/ijms18081732.
48. Bao S, Guo X, Yu S, Ding J, Tan L, Zhang F, et al. *Mycoplasma synoviae* enolase is a plasminogen/fibronectin binding protein. BMC Vet Res. 2014;10:223. https://doi.org/10.1186/s12917-014-0223-6.
49. Gründel A, Jacobs E, Dumke R. Interactions of surface-displayed glycolytic enzymes of *Mycoplasma pneumoniae* with components of the human extracellular matrix. Int J Med Microbiol. 2016;306:675–85. https://doi.org/10.1016/J.IJMM.2016.09.001.
50. Seymour LM, Jenkins C, Deutscher AT, Raymond BBA, Padula MP, Tacchi JL, et al. Mhp182 (P102) binds fibronectin and contributes to the recruitment of plasmin (ogen) to the *Mycoplasma hyopneumoniae* cell surface. Cell Microbiol. 2012;14:81–94. https://doi.org/10.1111/j.1462-5822.2011.01702.x.
51. Gründel A, Friedrich K, Pfeiffer M, Jacobs E, Dumke R. Subunits of the pyruvate dehydrogenase cluster of *Mycoplasma pneumoniae* are surface-displayed proteins that bind and activate human plasminogen. PLoS One. 2015;10:e0126600. https://doi.org/10.1371/journal.pone.0126600.
52. Yavlovich A, Katzenell A, Tarshis M, Higazi A-R, A, Rottem S. *Mycoplasma fermentans* binds to and invades HeLa cells: involvement of plasminogen and Urokinase. Infect Immun. 2004;72:5004–11.

53. Law RHP, Abu-ssaydeh D, Whisstock JC. ScienceDirect new insights into the structure and function of the plasminogen / plasmin system. Curr Opin Struct Biol. 2013;23:836–41. https://doi.org/10.1016/j.sbi.2013.10.006.
54. Bhattacharya S, Ploplis VA, Castellino FJ. Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination. J Biomed Biotechnol. 2012;2012:1–19. https://doi.org/10.1155/2012/482096.
55. Pickering AC, Vitry P, Prystopiuk V, Garcia B, Höök M, Schoenebeck J, et al. Host-specialized fibrinogen-binding by a bacterial surface protein promotes biofilm formation and innate immune evasion. PLoS Pathog. 2019;15:e1007816. https://doi.org/10.1371/journal.ppat.1007816.
56. Morgenthau A, Pogoutse A, Adamiak P, Moraes TF, Schryvers AB. Bacterial receptors for host transferrin and lactoferrin: molecular mechanisms and role in host-microbe interactions. Future Microbiol. 2013;8:1575–85.
57. Hegde S, Hegde SM, Rosengarten R, Chopra-Dewasthaly R. *Mycoplasma agalactiae* induces cytopathic effects in infected cells cultured in vitro. PLoS One. 2016;11. https://doi.org/10.1371/journal.pone.0163603.
58. Paes JA, Virginio VG, Cancela M, Leal FMA, Borges TJ, Jaeger N, et al. Pro-apoptotic effect of a *Mycoplasma hyopneumoniae* putative type I signal peptidase on PK(15) swine cells. Vet Microbiol. 2017;201:170–6. https://doi.org/10.1016/j.vetmic.2017.01.024.
59. Schmidl SR, Gronau K, Hames C, Busse J, Becher D, Hecker M, et al. The stability of Cytadherence proteins in *Mycoplasma pneumoniae* requires activity of the protein kinase PrkC †. Infect Immun. 2010;78:184–92. https://doi.org/10.1128/IAI.00958-09.
60. Liu Y, Zhou M, Xu S, Khan MA, Shi Y, Qu W, et al. *Mycoplasma bovis*-generated reactive oxygen species and induced apoptosis in bovine mammary epithelial cell cultures. J Dairy Sci. 2020;103:10429–45.
61. Bai F, Ni B, Liu M, Feng Z, Xiong Q, Shao G. *Mycoplasma hyopneumoniae*-derived lipid-associated membrane proteins induce inflammation and apoptosis in porcine peripheral blood mononuclear cells in vitro. Vet Microbiol. 2015;175:58–67.
62. Liu W, Shou C. *Mycoplasma hyorhinis* and *Mycoplasma fermentans* induce cell apoptosis and changes in gene expression profi les of 32D cells. Biol Res. 2011;44:383–91.
63. Hu W, Zhang W, Shah SWA, Ishfaq M, Li J. *Mycoplasma gallisepticum* infection triggered histopathological changes, oxidative stress and apoptosis in chicken thymus and spleen. Dev Comp Immunol. 2021;114:103832.
64. Amorim A, Marques L, Santos AMO, Martins H, Barbosa M, Rezende I, et al. Apoptosis in HEp-2 cells infected with *Ureaplasma diversum*. Biol Res. 2014;47:38. https://doi.org/10.1186/0717-6287-47-38.
65. Xue D, Li Y, Jiang Z, Deng G, Li M, Liu X, et al. A ROS-dependent and Caspase-3-mediated apoptosis in sheep bronchial epithelial cells in response to *Mycoplasma Ovipneumoniae* infections. Vet Immunol Immunopathol. 2017;187:55–63.
66. Silwedel C, Haarmann A, Fehrholz M, Claus H, Speer CP, Glaser K. More than just inflammation: *Ureaplasma* species induce apoptosis in human brain microvascular endothelial cells. J Neuroinflammation. 2019;16:38. https://doi.org/10.1186/s12974-019-1413-8.
67. Li Y, Jiang Z, Xue D, Deng G, Li M, Liu X, et al. *Mycoplasma ovipneumoniae* induces sheep airway epithelial cell apoptosis through an ERK signalling-mediated mitochondria pathway. BMC Microbiol. 2016;16:222. https://doi.org/10.1186/s12866-016-0842-0.
68. Zhang H, Zhao G, Guo Y, Menghwar H, Chen Y, Chen H, et al. *Mycoplasma bovis* MBOV_rs02825 encodes a secretory nuclease associated with cytotoxicity. Int J Mol Sci. 2016;17:628. https://doi.org/10.3390/ijms17050628.
69. Wu X, Zhang S, Long C, An Z, Xing X, Wen F, et al. *Mycoplasmas bovis* P48 induces apoptosis in EBL cells via an endoplasmic reticulum stress-dependent signaling pathway. Vet Microbiol. 2021;255:109013.
70. Zhao G, Zhu X, Zhang H, Chen Y, Schieck E, Hu C, et al. Novel secreted protein of *Mycoplasma bovis* MbovP280 induces macrophage apoptosis through CRYAB. Front Immunol. 2021;12:619362. https://doi.org/10.3389/fimmu.2021.619362.
71. Li P, Zhang Y, Li X, Zhou W, Li X, Jiang F, et al. *Mycoplasma hyopneumoniae* Mhp597 is a cytotoxicity, inflammation and immunosuppression associated nuclease. Vet Microbiol. 2019;235:53–62.
72. Liu W, Zhou D, Yuan F, Liu Z, Duan Z, Yang K, et al. Surface proteins mhp390 (P68) contributes to cilium adherence and mediates inflammation and apoptosis in *Mycoplasma hyopneumoniae*. Microb Pathog. 2019;126:92–100.
73. Yu Y, Zhang L, Chen Y, Li Y, Wang Z, Li G, et al. GroEL protein (heat shock protein 60) of *Mycoplasma gallisepticum* induces apoptosis in host cells by interacting with Annexin A2. Infect Immun. 2019;87. https://doi.org/10.1128/IAI.00248-19 .
74. Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012;8:1002772. https://doi.org/10.1371/journal.pgen.1002772.
75. Kim-Campbell N, Gomez H, Bayir H. Cell Death Pathways: Apoptosis and Regulated Necrosis. In: Critical Care Nephrology: Third Edition: Elsevier Inc.; 2019. p. 113–121.e2.
76. Yan S, Sorrell M, Berman Z. Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress. Cell Mol Life Sci. 2014;71:3951–67. https://doi.org/10.1007/s00018-014-1666-4.
77. Stracker TH, Petrini JHJ. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol. 2011;12:90–103. https://doi.org/10.1038/nrm3047.
78. Stoyanova T, Roy N, Kopanja D, Raychaudhuri P, Bagchi S. DDB2 (damaged-DNA binding protein 2) in nucleotide excision repair and DNA damage response. Cell Cycle. 2009;8:4067–71. https://doi.org/10.4161/cc.8.24.10109.
79. Suwaki N, Klare K, Tarsounas M. RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin Cell Dev Biol. 2011;22:898–905.
80. Sullivan MR, Bernstein KA. RAD-ical new insights into RAD51 regulation. Genes. 2018;9. https://doi.org/10.3390/genes9120629.
81. Ho-Tin-Noé B, Enslen H, Doeuvre L, Corsi JM, Lijnen HR, Anglés-Cano E. Role of plasminogen activation in neuronal organization and survival. Mol Cell Neurosci. 2009;42:288–95.
82. Jensch I, Gámez G, Rothe M, Ebert S, Fulde M, Somplatzki D, et al. PavB is a surface-exposed adhesin of *Streptococcus pneumoniae* contributing to nasopharyngeal colonization and airways infections. Mol Microbiol. 2010;77:22–43.
83. DaMassa AJ. Recovery of *Mycoplasma agalactiae* from mastitic goat milk. J Am Vet Med Assoc. 1983;183:548–9.
84. Chopra-Dewasthaly R, Zimmermann M, Rosengarten R, Citti C. First steps towards the genetic manipulation of *Mycoplasma agalactiae* and *Mycoplasma bovis* using the transposon Tn4001mod. Int J Med Microbiol. 2005;294:447–53. https://doi.org/10.1016/j.ijmm.2004.09.010.
85. Van Kuppeveld FJM, Van Der Logt JTM, Angulo AF, Van Zoest MJ, Quint WGV, Niesters HGM, et al. Genus-and species-specific identification of *mycoplasmas* by 16S rRNA amplification. Appl Environ Microbiol. 1992:2606–15.
86. Rawadi G, Roman-roman S, Thérapeutique Immunologie D, Uclaf R. Mycoplasma membrane lipoproteins induce Proinflammatory cytokines by a mechanism distinct from that of lipopolysaccharide. 1996. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC173813/ pdf/640637.pdf. Accessed 6 Sep 2019.
87. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem. 1981;256:1604–7.
88. Anderson TJC, Enabulele EE. Schistosoma mansoni. Trends Parasitol. 2021;37:176–7. https://doi.org/10.1016/j.pt.2020.06.003.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.